Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cordyceps sinensis spore powder (虫草被孢菌粉) is an approved natural product-based active pharmaceutical ingredient (API) manufactured by Zhejiang Changxing Pharmaceutical Co., Ltd. [1, 2, 4] It is derived from the fungus *Cordyceps sinensis*, which is widely used in Traditional Chinese Medicine (TCM). As an API, it is produced using deep fermentation technology and is intended for use in formulated drug products. [2, 4] While the manufacturer lists it as an approved product with the "Guoyao Zhunzi" (National Drug Standard) designation, specific details regarding its precise pharmacological mechanism of action and molecular targets are not well-characterized in publicly available sources. [1, 4] Based on the traditional use of *Cordyceps*, it is generally associated with immunomodulation, improving kidney and lung function, and anti-fatigue effects. [3, 8, 9, 11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cordyceps sinensis spore powder.